{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:46:08Z","timestamp":1791999968421,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T00:00:00Z","timestamp":1405641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12020-014-0354-3","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T14:02:40Z","timestamp":1405605760000},"page":"47-52","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Should we still be concerned about the potential side effects of glucagon-like peptide-1 receptor agonists on thyroid C cells?"],"prefix":"10.1007","volume":"48","author":[{"given":"Yang","family":"Cao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-Min","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,18]]},"reference":[{"key":"354_CR1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","volume":"79","author":"S Mojsov","year":"1987","unstructured":"S. Mojsov, G.C. Weir, J.F. Habener, Insulinotropin: glucagon-like peptide I (7\u201337) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas. J. Clin. Invest. 79, 616\u2013619 (1987)","journal-title":"J. Clin. Invest."},{"key":"354_CR2","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1136\/jcp.2006.043232","volume":"61","author":"LR Ranganath","year":"2008","unstructured":"L.R. Ranganath, Incretins: pathophysiological and therapeutic implications of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1. J. Clin. Pathol. 61, 401\u2013409 (2008)","journal-title":"J. Clin. Pathol."},{"key":"354_CR3","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1053\/j.gastro.2009.09.004","volume":"137","author":"A Maida","year":"2009","unstructured":"A. Maida, T. Hansotia, C. Longuet, Y. Seino, D.J. Drucker, Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice. Gastroenterology 137, 2146\u20132157 (2009)","journal-title":"Gastroenterology"},{"key":"354_CR4","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1210\/jc.2009-0921","volume":"94","author":"KJ Hare","year":"2009","unstructured":"K.J. Hare, F.K. Knop, M. Asmar, S. Madsbad, C.F. Deacon, J.J. Holst, T. Vilsb\u00f8ll, Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 94, 4679\u20134687 (2009)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"354_CR5","doi-asserted-by":"crossref","first-page":"3748","DOI":"10.1210\/en.2005-0473","volume":"146","author":"T Talsania","year":"2005","unstructured":"T. Talsania, Y. Anini, S. Siu, D.J. Drucker, P.L. Brubaker, Peripheral exendin-4 and peptide YY(3-36) synergistically reduce food intake through different mechanisms in mice. Endocrinology 146, 3748\u20133756 (2005)","journal-title":"Endocrinology"},{"issue":"Suppl. 5","key":"354_CR6","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1038\/sj.ijo.0801912","volume":"25","author":"M Tang-Christensen","year":"2001","unstructured":"M. Tang-Christensen, N. Vrang, P.J. Larsen, Glucagon-like peptide containing pathways in the regulation of feeding behaviour. Int. J. Obes. Relat. Metab. Disord. 25(Suppl. 5), S42\u2013S47 (2001)","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"354_CR7","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.regpep.2008.07.003","volume":"151","author":"H Linnebjerg","year":"2008","unstructured":"H. Linnebjerg, S. Park, P.A. Kothare, M.E. Trautmann, K. Mace, M. Fineman, I. Wilding, M. Nauck, M. Horowitz, Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. Regul. Pept. 151, 123\u2013129 (2008)","journal-title":"Regul. Pept."},{"key":"354_CR8","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1185\/03007990802418851","volume":"24","author":"RA DeFronzo","year":"2008","unstructured":"R.A. DeFronzo, T. Okerson, P. Viswanathan, X.S. Guan, J.H. Holcombe, L. MacConell, Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr. Med. Res. Opin. 24, 2943\u20132952 (2008)","journal-title":"Curr. Med. Res. Opin."},{"key":"354_CR9","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1210\/en.2009-1272","volume":"151","author":"L Bjerre Knudsen","year":"2010","unstructured":"L. Bjerre Knudsen, L.W. Madsen, S. Andersen, K. Almholt, A.S. Boer, D.J. Drucker, C. Gotfredsen, F.L. Egerod, A.C. Hegelund, H. Jacobsen, S.D. Jacobsen, A.C. Moses, A.M. M\u00f8lck, Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 151, 1473\u20131486 (2010)","journal-title":"Endocrinology"},{"key":"354_CR10","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1210\/en.2011-1864","volume":"153","author":"LW Madsen","year":"2012","unstructured":"L.W. Madsen, J.A. Knauf, C. Gotfredsen, A. Pilling, I. Sj\u00f6gren, S. Andersen, L. Andersen, A.S. Boer, K. Manova, A. Barlas, S. Vundavalli, N.C. Nyborg, L.B. Knudsen, A.M. Moelck, J.A. Fagin, GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 153, 1538\u20131547 (2012)","journal-title":"Endocrinology"},{"key":"354_CR11","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1056\/NEJMp1001578","volume":"362","author":"M Parks","year":"2010","unstructured":"M. Parks, C. Rosebraugh, Weighing risks and benefits of liraglutide-The FDA\u2019s review of a new antidiabetic therapy. N. Engl. J. Med. 362, 774\u2013777 (2010)","journal-title":"N. Engl. J. Med."},{"key":"354_CR12","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0014-5793(96)00895-2","volume":"393","author":"Y Lamari","year":"1996","unstructured":"Y. Lamari, C. Boissard, M.S. Moukhtar, A. Jullienne, G. Rosselin, J.M. Garel, Expression of glucagon-like peptide 1 receptor in a murine C cell line: regulation of calcitonin gene by glucagon-like peptide 1. FEBS Lett. 393, 248\u2013252 (1996)","journal-title":"FEBS Lett."},{"key":"354_CR13","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1210\/jc.2011-2407","volume":"97","author":"B Gier","year":"2012","unstructured":"B. Gier, P.C. Butler, C.K. Lai, D. Kirakossian, M.M. DeNicola, M.W. Yeh, Glucagon like peptide-1 receptor expression in the human thyroid gland. J. Clin. Endocrinol. Metab. 97, 121\u2013131 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"354_CR14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1159\/000330447","volume":"94","author":"B Waser","year":"2011","unstructured":"B. Waser, K. Beetschen, N.S. Pellegata, J.C. Reubi, Incretin receptors in non-neoplastic and neoplastic thyroid C cells in rodents and humans: relevance for incretin-based diabetes therapy. Neuroendocrinology 94, 291\u2013301 (2011)","journal-title":"Neuroendocrinology"},{"key":"354_CR15","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1210\/jc.2010-2318","volume":"96","author":"L Hegedus","year":"2011","unstructured":"L. Hegedus, A.C. Moses, M. Zdravkovic, T.L. Thi, G.H. Daniels, GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J. Clin. Endocrinol. Metab. 96, 853\u2013860 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"354_CR16","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/BF03346749","volume":"36","author":"M Gallo","year":"2013","unstructured":"M. Gallo, Thyroid safety in patients treated with liraglutide. J. Endocrinol. Invest. 36, 140\u2013145 (2013)","journal-title":"J. Endocrinol. Invest."},{"key":"354_CR17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.4158\/EP12358.OR","volume":"19","author":"AA Zayed","year":"2013","unstructured":"A.A. Zayed, M. Alzubaidi, S. Atallah, M.S. Momani, W.K. Al-Delaimy, Should food intake and circadian rhythm be considered when measuring serum calcitonin level? Endocr Pract. 19, 620\u2013626 (2013)","journal-title":"Endocr Pract."},{"key":"354_CR18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ejphar.2012.07.024","volume":"691","author":"D Bulchandani","year":"2012","unstructured":"D. Bulchandani, J.S. Nachnani, B. Herndon, A. Molteni, M.H. Pathan, T. Quinn, H.A. Hamdan, L.M. Alba, L. Graves, Effect of exendin (exenatide)-GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model. Eur. J. Pharmacol. 691, 292\u2013296 (2012)","journal-title":"Eur. J. Pharmacol."},{"key":"354_CR19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.regpep.2003.11.007","volume":"118","author":"M Blaker","year":"2004","unstructured":"M. Blaker, P. Arrenberg, I. Stange, M. Schulz, S. Burghardt, H. Michaelis, A. Pace, H. Greten, T. Schrenck, A. Weerth, The cholecystokinin2-receptor mediates calcitonin secretion, gene expression, and proliferation in the human medullary thyroid carcinoma cell line, TT. Regul. Pept. 118, 111\u2013117 (2004)","journal-title":"Regul.Pept."},{"key":"354_CR20","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1172\/JCI116708","volume":"92","author":"TC Wang","year":"1993","unstructured":"T.C. Wang, S. Bonner-Weir, P.S. Oates, M. Chulak, B. Simon, G.T. Merlino, E.V. Schmidt, S.J. Brand, Pancreatic gastrin stimulates islet differentiation of transforming growth factor to induced ductular precursor cells. J. Clin. Invest. 92, 1349\u20131356 (1993)","journal-title":"J. Clin. Invest."},{"issue":"12","key":"354_CR21","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1007\/BF02100139","volume":"41","author":"G Xu","year":"1996","unstructured":"G. Xu, S. Sumi, M. Koike, K. Tanigawa, Y. Nio, K.T. Mura, Role of endogenous hypergastrinemia in regenerating endocrine pancreas after partial pancreatectomy. Dig. Dis. Sci. 41(12), 2433\u20132439 (1996)","journal-title":"Dig. Dis. Sci."},{"key":"354_CR22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1007\/s00125-010-1825-6","volume":"53","author":"TB B\u00f6dvarsd\u00f3ttir","year":"2010","unstructured":"T.B. B\u00f6dvarsd\u00f3ttir, K.D. Hove, C.F. Gotfredsen, L. Pridal, A. Vaag, A.E. Karlsen, J.S. Petersen, Treatment with a proton pump inhibitor improves glycaemic control in Psammomys obesus, a model of type 2 diabetes. Diabetologia 53, 2220\u20132223 (2010)","journal-title":"Diabetologia"},{"key":"354_CR23","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.2337\/db08-0688","volume":"57","author":"WL Suarez-Pinzon","year":"2008","unstructured":"W.L. Suarez-Pinzon, R.F. Power, Y.H. Yan, C. Wasserfall, M. Atkinson, A. Rabinovitch, Combination therapy with glucagon-like peptide-1 and gastrin restores normoglycemia in diabetic NOD mice. Diabetes 57, 3281\u20133288 (2008)","journal-title":"Diabetes"},{"key":"354_CR24","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1007\/s00125-009-1390-z","volume":"52","author":"WL Suarez-Pinzon","year":"2009","unstructured":"W.L. Suarez-Pinzon, G.S. Cembrowski, A. Rabinovitch, Combination therapy with a dipeptidyl peptidase-4 inhibitor and a proton pump inhibitor restores normoglycaemia in non-obese diabetic mice. Diabetologia 52, 1680\u20131682 (2009)","journal-title":"Diabetologia"},{"key":"354_CR25","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/j.1463-1326.2012.01676.x","volume":"15","author":"K Fosgerau","year":"2013","unstructured":"K. Fosgerau, L. Jessen, J.L. Tolborg, T. \u00d8sterlund, K.S. Larsen, K. Rolsted, M. Brorson, J. Jelsing, T.S.R. Neerup, The novel GLP-1-gastrin dual agonist, ZP3022, increases \u03b2 -cell mass and prevents diabetes in db\/db mice. Diabetes Obes. Metab. 15, 62\u201371 (2013)","journal-title":"Diabetes Obes. Metab."},{"key":"354_CR26","doi-asserted-by":"crossref","first-page":"E2105","DOI":"10.1210\/jc.2012-1720","volume":"97","author":"PK Singh","year":"2012","unstructured":"P.K. Singh, D. Hota, P. Dutta, N. Sachdeva, A. Chakrabarti, A. Srinivasan, I. Singh, A. Bhansali, Pantoprazole improves glycemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled trial. J. Clin. Endocrinol. Metab. 97, E2105\u2013E2108 (2012)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"354_CR27","first-page":"1377","volume":"57","author":"JC Reubi","year":"1997","unstructured":"J.C. Reubi, J.C. Schaer, B. Waser, Cholecystokinin (CCK)-A and CCK-B\/gastrin receptors in human tumors. Cancer Res. 57, 1377\u20131386 (1997)","journal-title":"Cancer Res."},{"key":"354_CR28","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1093\/clinchem\/48.9.1505","volume":"48","author":"G Vitale","year":"2002","unstructured":"G. Vitale, A. Ciccarelli, M. Caraglia, M. Galderisi, R. Rossi, S.D. Prete, A. Abbruzzese, G. Lupoli, Comparison of two provocative tests for calcitonin in medullary thyroid carcinoma: omeprazole vs pentagastrin. Clin. Chem. 48, 1505\u20131510 (2002)","journal-title":"Clin. Chem."},{"issue":"s1","key":"354_CR29","doi-asserted-by":"crossref","first-page":"217s","DOI":"10.1111\/j.1365-2265.1976.tb03830.x","volume":"5","author":"BA Roos","year":"1976","unstructured":"B.A. Roos, L.J. Deftos, Regulation of calcitonin secretion in vitro. Clin Endocrinol. Suppl.5, 217s\u2013222s (1976)","journal-title":"Clin Endocrinol."},{"key":"354_CR30","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1056\/NEJM197303292881301","volume":"288","author":"GW Sizemore","year":"1973","unstructured":"G.W. Sizemore, V.L.W. Go, E.L. Kaplan, L.J. Sanzenbacher, K.H. Holtermuller, C.D. Arnaud, Relations of calcitonin and gastrin in the Zollinger\u2013Ellison syndrome and medullary carcinoma of the thyroid. N. Engl. J. Med. 288, 641\u2013644 (1973)","journal-title":"N. Engl. J. Med."},{"key":"354_CR31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1007\/BF01072883","volume":"23","author":"C Owyang","year":"1978","unstructured":"C. Owyang, H. Heath, G.W. Sizemore, V.L. Go, Comparison of the effects of pentagastrin and meal-stimulated gastrin on plasma calcitonin in normal man. Am J Dig Dis.23, 1084\u20131088 (1978)","journal-title":"Am. J. Dig. Dis."},{"key":"354_CR32","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1159\/000198477","volume":"20","author":"CB Lamers","year":"1980","unstructured":"C.B. Lamers, W.H. Hackeng, T. Thien, J.H. Tongeren, Serum concentrations of immunoreactive calcitonin in patients with hypergastrinemia. Digestion 20, 379\u2013382 (1980)","journal-title":"Digestion"},{"key":"354_CR33","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/BF03347369","volume":"29","author":"MF Erdogan","year":"2006","unstructured":"M.F. Erdogan, A. Gursoy, M. Kulaksizoglu, Long-term effects of elevated gastrin levels on calcitonin secretion. J. Endocrinol. Invest. 29, 771\u2013775 (2006)","journal-title":"J. Endocrinol. Invest."},{"key":"354_CR34","first-page":"357","volume":"27","author":"E Bertin","year":"2001","unstructured":"E. Bertin, N. Schneider, N. Abdelli, H. Wampach, G. Cadiot, A. Loboguerrero, M. Leutenegger, J.C. Liehn, G. Thiefin, Gastric emptying is accelerated in obese type 2 diabetic patients without autonomic neuropathy. Diabetes Metab. 27, 357\u2013364 (2001)","journal-title":"Diabetes Metab."},{"key":"354_CR35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF02298958","volume":"11","author":"I Migdalis","year":"2001","unstructured":"I. Migdalis, T. Thomaides, C. Chairopoulos, C. Kalogeropoulou, J. Charalabides, F. Mantzara, Changes of gastric emptying rate and gastrin levels are early indicators of autonomic neuropathy in type II diabetic patients. Clin. Auton. Res. 11, 259\u2013263 (2001)","journal-title":"Clin. Auton. Res."},{"issue":"2","key":"354_CR36","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/j.1753-0407.2012.00227.x","volume":"5","author":"V Patel","year":"2013","unstructured":"V. Patel, A. Joharapurkar, T. Gandhi, K. Patel, N. Dhanesha, S. Kshirsagar, V. Dhote, J. Detroja, R. Bahekar, M. Jain, Omeprazole improves the antiobesity and antidiabetic effects of exendin-4 in db\/db mice (-4 db\/db)*. J diabetes. 5(2), 163\u2013171 (2013)","journal-title":"J. diabetes"},{"key":"354_CR37","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0024-3205(94)00489-7","volume":"55","author":"R Eissele","year":"1994","unstructured":"R. Eissele, E. Bothe-Sandfort, B. G\u00f6ke, J. Eng, R. Arnold, H. Koop, Rat gastric somatostatin and gastrin release: interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide. Life Sci. 55, 629\u2013634 (1994)","journal-title":"Life Sci."},{"key":"354_CR38","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1139\/y94-172","volume":"72","author":"X Jia","year":"1994","unstructured":"X. Jia, J.C. Brown, Y.N. Kwok, R.A. Pederson, C.H. McIntosh, Gastric inhibitory polypeptide and glucagon-like peptide-1 (7\u201336) amide exert similar effects on somatostatin secretion but opposite effects on gastrin secretion from the rat stomach. Can. J. Physiol. Pharmacol. 72, 1215\u20131219 (1994)","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"354_CR39","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3109\/00365529009095514","volume":"25","author":"R Eissele","year":"1990","unstructured":"R. Eissele, H. Koop, R. Arnold, Effect of glucagon-like peptide-1 on gastric somatostatin and gastrin secretion in the rat. Scand. J. Gastroenterol. 25, 449\u2013454 (1990)","journal-title":"Scand. J. Gastroenterol."},{"key":"354_CR40","unstructured":"Food and Drug Administration, Forteo (teriparatide), medical review 2002: Part 3. (2002). http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2002\/21-318_FORTEO_Medr_P3.pdf"},{"key":"354_CR41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1530\/acta.0.1000041","volume":"100","author":"V Thurston","year":"1982","unstructured":"V. Thurston, E.D. Williams, Experimental induction of C cell tumours in thyroid by increased dietary content of vitamin D3. Acta Endocrinol. 100, 41\u201345 (1982)","journal-title":"Acta Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0354-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12020-014-0354-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-014-0354-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T10:27:32Z","timestamp":1598092052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12020-014-0354-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,18]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1007\/s12020-014-0354-3","relation":{},"ISSN":["1355-008X","1559-0100"],"issn-type":[{"value":"1355-008X","type":"print"},{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,18]]}}}